Source: Mint
New Delhi, August 5, 2025 – Welcure Drugs & Pharmaceuticals’ shares, a low-priced penny stock, hit the 5% upper circuit on Tuesday, August 5. They reached an intraday high of ₹10.11 per share, which was also the upper price band for the day. This surge unfolded while the Indian stock market was undergoing selling pressure.
Solid performance reporting in the first quarter
Welcure reported exceptional revenue and profit growth for the quarter ended June 2025 as compared to the previous quarter. Revenue increased from ₹21.21 crore for Q4FY25 to ₹299.91 crore in Q1FY26 for a growth of 1,300%. Net profit increased from ₹2.5 crore to ₹23.29 crore, an increase of 830% quarter on quarter.
The company credited this performance to its business strategy and shift towards a fee-based, asset-light model. In a statement, the management said, “The strong financial performance in Q1FY26 is a reflection of our business strategies, meticulous decisions, and our focused transition to a fee-based, asset-light model. We are committed to sustaining this performance through efficient supply chain management and product diversification.”
Changes in Leadership
As part of paving the way for future expansion, the company announced new appointments to its board of directors today.
- Rabi Thakor has been appointed to the role of an additional non-executive non-independent director.
- Yogeshkumar Prajapati and Bhumika Pradhan have been appointed as additional independent directors.
- These Director changes are also aimed at building better governance as well as keeping the future in mind to support long-term planning of the business.
Summary of Stock Price Performance
Welcure has had mixed stock price performance in the short term, but has been a very strong performer in the long term. years and went up 660% over the past 5 years total. This shows that whilst there can be volatility as a share in the short-term, longer term it has been a multibagger.
Conclusion: Welcure Drugs & Pharmaceuticals has gained traction after delivering impressive Q1 results, prompting its stock to move to the upper circuit even in a poor market environment. The financial picture is looking much better with a new management outlook focused on growth. However, as this is a penny stock, it is always wise to be cautious given that these types of stocks move at wild pace on price.
